GlobeNewswire: NuCana plc Contains the last 10 of 123 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:44:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853631/0/en/NuCana-Announces-Plan-to-Implement-ADS-Ratio-Change.html?f=22&fvtc=4&fvtv=38258NuCana Announces Plan to Implement ADS Ratio Change2024-03-27T20:30:00Z<![CDATA[EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on or about April 16, 2024 (the "Effective Date").]]>https://www.globenewswire.com/news-release/2024/03/20/2849759/0/en/NuCana-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=38258NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update2024-03-20T20:01:00Z<![CDATA[Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety]]>https://www.globenewswire.com/news-release/2024/02/27/2835937/0/en/NuCana-to-Present-at-TD-Cowen-s-44th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=38258NuCana to Present at TD Cowen’s 44th Annual Health Care Conference2024-02-27T13:00:00Z<![CDATA[EDINBURGH, United Kingdom, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at TD Cowen’s 44th Annual Health Care Conference.]]>https://www.globenewswire.com/news-release/2024/02/06/2824278/0/en/NuCana-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=38258NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-06T13:00:00Z<![CDATA[EDINBURGH, United Kingdom, Feb. 06, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.]]>https://www.globenewswire.com/news-release/2023/11/16/2782226/0/en/NuCana-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=38258NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-16T21:01:00Z<![CDATA[Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data]]>https://www.globenewswire.com/news-release/2023/11/10/2778505/0/en/NuCana-Announces-Listing-Transfer-to-Nasdaq-Capital-Market.html?f=22&fvtc=4&fvtv=38258NuCana Announces Listing Transfer to Nasdaq Capital Market2023-11-10T21:01:00Z<![CDATA[EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on November 9, 2023.]]>https://www.globenewswire.com/news-release/2023/11/08/2776655/0/en/NuCana-to-Present-at-the-Jefferies-London-Healthcare-Conference.html?f=22&fvtc=4&fvtv=38258NuCana to Present at the Jefferies London Healthcare Conference2023-11-08T21:01:00Z<![CDATA[EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference.]]>https://www.globenewswire.com/news-release/2023/11/01/2771668/0/en/NuCana-to-Participate-in-the-Truist-Securities-2023-BioPharma-Symposium.html?f=22&fvtc=4&fvtv=38258NuCana to Participate in the Truist Securities 2023 BioPharma Symposium2023-11-01T20:01:00Z<![CDATA[EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Truist Securities 2023 BioPharma Symposium.]]>https://www.globenewswire.com/news-release/2023/10/16/2760475/0/en/NuCana-Presents-Promising-Data-on-NUC-7738-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-2023.html?f=22&fvtc=4&fvtv=38258NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 20232023-10-16T11:00:00Z<![CDATA[Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy]]>https://www.globenewswire.com/news-release/2023/10/13/2760081/0/en/NuCana-Presents-Encouraging-Data-on-NUC-3373-in-Colorectal-Cancer-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-2023.html?f=22&fvtc=4&fvtv=38258NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 20232023-10-13T16:30:00Z<![CDATA[NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients]]>